Documented Case Study · Fully Cited · No Commercial Agenda
What if mold illness treatment started with restoring your cells’ ability to produce energy?
A patient-driven, science-based informational platform documenting one case of invasive aspergillosis treated with an energy-first approach. Measurable functional improvement within 28 days. Full pharmacological rationale. Every claim cited.
This is not a product. This is not a protocol to follow. This is information you can bring to your doctor.
The Core Thesis
Most mold illness protocols focus on killing the pathogen and correcting biomarkers. This approach starts somewhere else.
The Problem
Mycotoxins damage mitochondria
Mold toxins directly impair the mitochondria responsible for producing ATP, your cells’ energy currency. When cellular energy production is compromised, every downstream system suffers: detoxification pathways can’t run, immune function degrades, and healing stalls. This is why so many patients feel like they’re “doing everything right” and getting nowhere.
The Hypothesis
Restore energy first, then fight the infection
If the body doesn’t have the energy to detoxify, adding more detox interventions is like asking a car with an empty tank to drive to the mechanic. The approach documented here prioritizes restoring mitochondrial function and ATP production before or simultaneously with antimicrobial and detoxification interventions.
The Approach
Pharmacologically rationalized, fully cited
Every compound in the protocol was selected for a specific mechanism of action, with published evidence supporting its use. No proprietary blends. No “buy our stack.” Every compound identified by generic name with dosing rationale. Source it from anywhere.
The Limitation
One case study, honestly presented
This is a single patient’s documented experience, not a clinical trial. Individual results will vary based on genetics, infection type, severity, and medical supervision. We are explicit about what we know, what we think, what we don’t know, and the difference between those three things.
Case Study: Invasive Aspergillosis Treated with an Energy-First Protocol
A patient with active invasive aspergillosis, one of the most severe forms of mold-related illness, documented functional improvement within 28 days using a protocol that prioritized cellular energy restoration alongside targeted antimicrobial and detoxification interventions.
functional improvement
increase (50ft to 200ft)
with published evidence
The case study includes: complete timeline with dated observations, full compound list with mechanisms of action and citations, CYP450 interaction analysis, EDS-specific treatment modifications, and an honest accounting of what improved, what didn’t, and what remains unknown.
Read the Full Case StudyThis case study is pending review by qualified physicians and researchers. The content may be updated based on expert feedback. All corrections are documented in the public changelog.
Deep Dives
Each topic explored with full mechanism-of-action detail and published citations.
ATP and Mitochondrial Restoration
Why cellular energy production is the foundation, and how d-ribose, CoQ10, NAD+ precursors, and PQQ support recovery at the mitochondrial level.
Antifungal Strategy
Pharmaceutical and botanical antifungals, mechanism of action for each, biofilm disruption, and why combination approaches matter.
Mycotoxin Clearance
How mycotoxins are metabolized and eliminated, binder comparison, probiotic binding mechanisms, and clearance monitoring.
Immune Modulation
Peptide therapy (thymosin alpha-1, BPC-157, selank), mast cell stabilization, and immune support during active infection.
EDS and Mold Illness
How Ehlers-Danlos Syndrome and connective tissue disorders complicate mold illness, and what treatment modifications matter.
Protocol Comparison
Analysis of Shoemaker, Brewer, Nathan, Crista, and ISEAI approaches. Where they work, where they fall short, and how this differs.
For Patients
If you’re reading this because you’re sick and nothing is working, you’re in the right place. This site was built by someone who was where you are. The information here is written so you can understand it and bring it to your doctor. No jargon walls. No gatekeeping. No sales pitch.
Start here →For Practitioners
If you’re a clinician looking for approaches beyond the standard Shoemaker framework, this resource provides a fully cited, mechanism-based rationale for an energy-first treatment model. Designed so you can evaluate the science on its own merits and apply what’s relevant to your practice.
Practitioner summary →What This Site Is (and Isn’t)
Information, Not Advice
Every page includes clear disclaimers. This is educational content to discuss with your healthcare provider, not instructions to follow independently.
Cited, Not Claimed
Every factual claim includes author, journal, year, and PMID or DOI. When evidence is limited or extrapolated, we say so explicitly.
No Commercial Agenda
No supplement line. No affiliate links. No paid memberships. No proprietary blends. Every compound is identified by generic name so you can source it anywhere.
Openly Correctable
We welcome scientific correction and maintain a public changelog. If we got something wrong, we fix it, document the change, and thank whoever pointed it out.
One Case, Honestly
This is not a clinical trial. It is one documented experience. We distinguish between what we know, what we think, and what we don’t know yet.
Built by a Patient
This site was created by someone who is actively recovering from invasive aspergillosis because the information she needed didn’t exist anywhere else.